NASDAQ:NXTC NextCure (NXTC) Stock Price, News & Analysis $7.72 -0.56 (-6.76%) As of 01:24 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About NextCure Stock (NASDAQ:NXTC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NextCure alerts:Sign Up Key Stats Today's Range$7.54▼$8.1350-Day Range$1.60▼$8.2852-Week Range$1.55▼$15.74Volume112,720 shsAverage Volume902,166 shsMarket Capitalization$27.87 millionP/E RatioN/ADividend YieldN/APrice Target$19.00Consensus RatingHold Company Overview NextCure, Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development. The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation. Lead programs such as NX-1607, an oral small molecule inhibitor targeting the CD200 checkpoint, and NX-0255, a monoclonal antibody directed against KIR3DL2, are being developed for solid tumors and hematologic malignancies. NextCure is also advancing NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, into studies for B-cell malignancies. Strategic partnerships with global pharmaceutical companies support NextCure’s efforts to expand its research capabilities and accelerate clinical programs across oncology and immunology indications. Founded in 2013 and headquartered in Beltsville, Maryland, NextCure operates state‐of‐the‐art research and development facilities in the greater Washington, D.C. area. The company conducts clinical trials across North America and Europe, collaborating with leading academic institutions and healthcare centers. By combining novel target discovery with rigorous translational and clinical research, NextCure seeks to bring new immunotherapeutic options to patients worldwide.AI Generated. May Contain Errors. Read More NextCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreNXTC MarketRank™: NextCure scored higher than 90% of companies evaluated by MarketBeat, and ranked 101st out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingNextCure has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNextCure has a consensus price target of $19.00, representing about 144.7% upside from its current price of $7.77.Amount of Analyst CoverageNextCure has only been the subject of 3 research reports in the past 90 days.Read more about NextCure's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NextCure are expected to grow in the coming year, from ($7.99) to ($6.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NextCure is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NextCure is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNextCure has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.44% of the float of NextCure has been sold short.Short Interest Ratio / Days to CoverNextCure has a short interest ratio ("days to cover") of 0.16, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NextCure has recently decreased by 89.33%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNextCure does not currently pay a dividend.Dividend GrowthNextCure does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.96 News SentimentNextCure has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for NextCure this week, compared to 2 articles on an average week.Search Interest6 people have searched for NXTC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added NextCure to their MarketBeat watchlist in the last 30 days. Company Ownership3.8 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $1,710,807.00 in company stock, which represents 6.1031% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, NextCure insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,710,807.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders11.90% of the stock of NextCure is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.65% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NextCure's insider trading history. Receive NXTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NXTC Stock News HeadlinesAvere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001August 10, 2026 | prnewswire.comNextCure Provides Business Update and Reports Second Quarter 2026 Financial ResultsAugust 6, 2026 | markets.businessinsider.comThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's pullback from highs above 4000 an ounce. Yet top junior mining assets remain priced as if gold were still stuck near 1800 an ounce, a gap analyst Garrett Goggin calls the Golden Anomaly. With record cash on hand, majors may soon be forced to buy juniors to secure future production.August 14 at 1:00 AM | Golden Portfolio (Ad)NextCure (NASDAQ:NXTC) Major Shareholder Adar1 Capital Management, Llc Purchases 36,303 Shares of StockAugust 4, 2026 | insidertrades.comNextCure (NASDAQ:NXTC) Major Shareholder Adar1 Capital Management, Llc Buys 292,850 Shares of StockAugust 4, 2026 | americanbankingnews.comInsider Buying: NextCure (NASDAQ:NXTC) Major Shareholder Acquires $17,050.00 in StockJuly 30, 2026 | insidertrades.comThe M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—VEEE, NXTC, TCBK, and FHBJuly 23, 2026 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—VEEE, NXTC, TCBX, and FHBJuly 21, 2026 | globenewswire.comSee More Headlines NXTC Stock Analysis - Frequently Asked Questions How have NXTC shares performed this year? NextCure's stock was trading at $14.19 at the start of the year. Since then, NXTC shares have decreased by 45.3% and is now trading at $7.7650. How were NextCure's earnings last quarter? NextCure, Inc. (NASDAQ:NXTC) posted its quarterly earnings data on Thursday, August, 6th. The company reported ($2.80) EPS for the quarter, missing the consensus estimate of ($1.95) by $0.85. When did NextCure's stock split? Shares of NextCure reverse split on Monday, July 14th 2025.The 1-12 reverse split was announced on Friday, June 20th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, July 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did NextCure IPO? NextCure (NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO. How do I buy shares of NextCure? Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NextCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that NextCure investors own include Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings8/06/2026Today8/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 NXTC's financial health is in the Green zone, according to TradeSmith. NXTC has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NXTC CIK1661059 Webwww.nextcure.com Phone(240) 399-4900FaxN/AEmployees90Year Founded2015Price Target and Rating Average Price Target for NextCure$19.00 High Price Target$20.00 Low Price Target$18.00 Potential Upside/Downside+145.0%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($8.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-154.62% Return on Assets-100.19% Debt Debt-to-Equity RatioN/A Current Ratio3.47 Quick Ratio3.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.36 per share Price / Book2.31Miscellaneous Outstanding Shares3,610,000Free Float3,182,000Market Cap$28.00 million OptionableNo Data Beta1.27 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:NXTC) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe options guide that actually starts at the beginningMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"The US just hit $39 trillion in debt. Interest alone is now over $1 trillion a year, more than the entire defe...Decentralized Masters | SponsoredAfter KDA, PRE, and OCEAN—this is the one17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
